Clinical Advances in Atopic Dermatitis and Alopecia Areata

Released On
July 1, 2022

Expires On
July 1, 2023

Media Type

Completion Time
60 minutes

Allergy & Immunology, Dermatology

Alopecia Areata, Atopic Dermatitis, Pediatrics

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by The American Academy of PAs and The France Foundation.

This activity is supported in part by an independent education grant from Pfizer.

Credit Available

  • Nurses — 1.0 Contact Hours

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of nurses involved in the care of patients with atopic dermatitis (AD) and alopecia areata (AA).

Program Overview

This activity will cover patient-centered care for AD and AA through a greater understanding of their immunological pathways, treatment considerations, impact of these conditions on patients’ quality of life, the latest data on emerging treatment, and how to apply this information into practice.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review the pathophysiologic underpinnings of AD and AA
  • Describe the risk factors and common comorbidities associated with AD and AA
  • Explain the burden of disease of AD and AA from a holistic standpoint, incorporating clinical and psychosocial elements
  • Summarize clinical profiles of novel and emerging therapies, including MOAs, efficacy, and safety



Kimberly K. Dempsey, EdD, MPA, PA-C, DFAAPA

Associate Professor
Eastern Virginia Medical School
Eastern Virginia Medical School
Norfolk, VA


Terri Nagy, MPAS, PA-C, DFAAPA

Dermatology Physician Assistant
Vanguard Skin Specialists
Diplomate Fellow, SDPA
Colorado Springs, CO


Leigh Ann Pansch, MSN, FNP-BC, DCNP

Dermatology Certified Nurse Practitioner
Dermatologists of Central States
Cincinnati, Ohio
Nurse Planner

Nurse Planner

Khamini Guillermo, DNP, CRNP

Ursinus College
Collegeville, Pennsylvania

Accreditation Statement

This nursing continuing professional development activity was approved by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center’s Commission on Accreditation.

For more information regarding contact hours, please call The France Foundation (860) 434-1650.

Credit Designation

1.0 total contact hour(s) of continuing nursing education.

Disclosure of Relevant Financial Relationship

Kimberly K. Dempsey, EdD, MPA, PA-C, DFAAPA, has no relevant financial relationships to disclose.

Khamini Guillermo, DNP, CRNP, has no relevant financial relationships to disclose.

Terri Nagy, MPAS, PA-C, DFAAPA, has no relevant financial relationships to disclose.

Leigh Ann Pansch, MSN, FNP-BC, DCNP
  • Consultant: Novartis, Pfizer
  • Speaker’s Bureau: AbbVie, Eli Lilly, and Sanofi-Regeneron

All of the relevant financial relationships listed for this individual have been mitigated.

The planners, staff, and reviewers at the American Academy of Physician Assistants and The France Foundation have nothing to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CE credit for this enduring activity. To receive CE credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
  4. Complete the posttest with a passing score of 75% or above

Certificates will be emailed to the participant.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. The AAPA and The France Foundation do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.


The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients.

Contact Information

For CME questions please contact: